

A provider briefing on Turqoz 28 Day availability in 2026. Learn about supply challenges, prescribing implications, and tools to help patients.
If your patients have been reporting difficulty filling prescriptions for Turqoz 28 Day (norgestrel/ethinyl estradiol 0.3 mg/0.03 mg), you're hearing a real concern. While Turqoz is not in a formal FDA drug shortage, its status as a newer brand-name combined oral contraceptive with no generic equivalent creates persistent availability challenges at the pharmacy level.
This article provides a clinical and logistical overview for prescribers — including current supply status, prescribing considerations, cost and access information, and tools to improve patient outcomes.
Turqoz was brought to market by Lupin Pharmaceuticals as a combined oral contraceptive containing norgestrel 0.3 mg and ethinyl estradiol 0.03 mg in a standard 21/7 regimen (21 active tablets plus 7 placebo tablets).
As a newer entrant in a crowded oral contraceptive market, Turqoz faces the same distribution challenges common to recently launched brand-name medications:
These factors combine to create a situation where the drug is technically available but functionally hard for patients to obtain.
When prescribing Turqoz 28 Day, consider the following:
Turqoz uses norgestrel — a racemic mixture of levonorgestrel and dextronorgestrel — paired with ethinyl estradiol. While pharmacologically related to levonorgestrel-containing COCs, Turqoz is not AB-rated to any other oral contraceptive, meaning pharmacists cannot automatically substitute another product.
Availability issues directly threaten contraceptive adherence. Patients who cannot fill their Turqoz prescription may:
Proactive communication about backup options can mitigate these risks.
If a patient cannot obtain Turqoz, switching to another combined oral contraceptive is generally straightforward. Comparable options include:
Instruct patients to start the new COC the day after their last active Turqoz tablet, or on the first day of their next menses. Consider recommending 7 days of backup contraception during the transition.
As of early 2026:
The disconnect between "available from the manufacturer" and "on pharmacy shelves" is the primary patient barrier.
Understanding the cost landscape helps when counseling patients:
For patients facing cost barriers, refer them to our guide on saving money on Turqoz 28 Day.
Several tools can help you and your care team support patients who are struggling to find Turqoz:
Medfinder offers real-time pharmacy stock checking, allowing your staff to verify which nearby pharmacies have Turqoz in stock before sending a prescription. This can prevent the frustrating cycle of rejected fills and pharmacy transfers.
For supply questions, providers can contact Lupin at 1-800-399-2561 or visit lupinpharmaceuticals.com for distribution and availability information.
For uninsured or underinsured patients:
Several trends may improve Turqoz accessibility over time:
In the meantime, prescribers play a critical role in managing patient expectations and providing seamless transitions to alternative contraceptives when needed.
Turqoz 28 Day is not in a formal shortage, but its real-world availability remains inconsistent in 2026. As a prescriber, you can make a significant difference by:
For a practical step-by-step workflow, see our companion article: How to help your patients find Turqoz 28 Day in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.